Evidence map›Paper›PMID 37696888›Full record

ArticleNature communications2023

A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles.

Kangfu Chen, Bill T V Duong, Sharif U Ahmed, Piriththiv Dhavarasa, Zongjie Wang, Mahmoud Labib, Connor Flynn, Jingya Xu, Yi Y Zhang, Hansen Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Role of Microglia in Glaucomatous Pathology.Advances in experimental medicine and biology · 2025
    Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kangfu Chen *Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-5077-2223
Bill T V Duong *Department of Chemistry, University of Toronto, Toronto, ON, Canada.
Sharif U AhmedDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.
Piriththiv DhavarasaDepartment of Biochemistry, University of Toronto, Toronto, ON, Canada.
Zongjie WangDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, USA.ORCID http://orcid.org/0000-0001-9900-7197
Mahmoud LabibDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-4565-2056
Connor FlynnDepartment of Chemistry, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0009-0009-5692-5719
Jingya XuDepartment of Chemistry, University of Toronto, Toronto, ON, Canada.
Yi Y ZhangDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.
Hansen WangDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-4414-3372
Xiaolong YangDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.
Jagotamoy DasDepartment of Chemistry, Northwestern University, Evanston, IL, USA.ORCID http://orcid.org/0000-0003-2724-1827
Hossein ZargartalebiDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.
Yuan MaDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.
Shana O KelleyDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada. shana.kelley@northwestern.edu.ORCID http://orcid.org/0000-0003-3360-5359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomal PD-L1 (exoPD-L1) has recently received significant attention as a biomarker predicting immunotherapeutic responses involving the PD1/PD-L1 pathway. However, current technologies for exosomal analysis rely primarily on bulk measurements that do not consider the heterogeneity found within exosomal subpopulations. Here, we present a nanoscale cytometry platform NanoEPIC, enabling phenotypic sorting and exoPD-L1 profiling from blood plasma. We highlight the efficacy of NanoEPIC in monitoring anti-PD-1 immunotherapy through the interrogation of exoPD-L1. NanoEPIC generates signature exoPD-L1 patterns in responders and non-responders. In mice treated with PD1-targeted immunotherapy, exoPD-L1 is correlated with tumor growth, PD-L1 burden in tumors, and the immune suppression of CD8+ tumor-infiltrating lymphocytes. Small extracellular vesicles (sEVs) with different PD-L1 expression levels display distinctive inhibitory effects on CD8 + T cells. NanoEPIC offers robust, high-throughput profiling of exosomal markers, enabling sEV subpopulation analysis. This platform holds the potential for enhanced cancer screening, personalized treatment, and therapeutic response monitoring.

Indexed as

B7-H1 AntigenExtracellular VesiclesAnimalsCD8-Positive T-LymphocytesCell MovementImmunosuppression TherapyMiceB7-H1 Antigen

Identifiers

PMID37696888
PMCPMC10495366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.